Ftse Mib
33.249,09
1,04%
DAX
18.100,90
0,15%
S&P 500
5.479,09
0,11%
NASDAQ
17.874,47
0,10%
Bitcoin
65.056,73
-2,14%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Adaptimmune Therapeutics PLC (ADAP) Adaptimmune Therapeutics PLC (ADAP) Notizie

ADAP

Adaptimmune Therapeutics (ADAP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ADAP
DataOraFonteTitoloSimboloCompagnia
11/06/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADAPAdaptimmune Therapeutics PLC
17/01/202423:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADAPAdaptimmune Therapeutics PLC
30/11/202322:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ADAPAdaptimmune Therapeutics PLC
08/11/202322:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADAPAdaptimmune Therapeutics PLC
10/08/202322:05Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ADAPAdaptimmune Therapeutics PLC
29/06/202322:54Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:ADAPAdaptimmune Therapeutics PLC
29/06/202322:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ADAPAdaptimmune Therapeutics PLC
01/06/202322:49Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ADAPAdaptimmune Therapeutics PLC
22/05/202313:02Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:ADAPAdaptimmune Therapeutics PLC
12/05/202322:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ADAPAdaptimmune Therapeutics PLC
21/04/202312:04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:ADAPAdaptimmune Therapeutics PLC
13/04/202314:01Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:ADAPAdaptimmune Therapeutics PLC
12/04/202300:33Dow Jones NewsADRs End Higher, Adaptimmune Therapeutics and Alibaba Trade ActivelyNASDAQ:ADAPAdaptimmune Therapeutics PLC
05/04/202322:41Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:ADAPAdaptimmune Therapeutics PLC
03/04/202314:01Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:ADAPAdaptimmune Therapeutics PLC
14/02/202322:20Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:ADAPAdaptimmune Therapeutics PLC
18/11/202219:55TipRanksAdaptimmune Therapeutics (ADAP) Gets a Buy from Mizuho SecuritiesNASDAQ:ADAPAdaptimmune Therapeutics PLC
10/11/202205:35TipRanksSVB Securities Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
26/10/202223:55TipRanksMizuho Securities Keeps Their Hold Rating on Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
10/09/202200:02Dow Jones NewsADRs End Higher, Argo Blockchain and Adaptimmune Therapeutics Trade ActivelyNASDAQ:ADAPAdaptimmune Therapeutics PLC
06/09/202201:05TipRanksMizuho Securities Sticks to Their Hold Rating for Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
05/08/202217:35TipRanksAdaptimmune Therapeutics (ADAP) Receives a Buy from JonesTradingNASDAQ:ADAPAdaptimmune Therapeutics PLC
04/08/202219:15TipRanksAdaptimmune Therapeutics (ADAP) Gets a Hold Rating from Mizuho SecuritiesNASDAQ:ADAPAdaptimmune Therapeutics PLC
01/07/202223:04Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ADAPAdaptimmune Therapeutics PLC
17/05/202200:25TipRanksMizuho Securities Remains a Hold on Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
16/05/202223:00GlobeNewswire Inc.Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCTNASDAQ:ADAPAdaptimmune Therapeutics PLC
09/05/202222:52Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ADAPAdaptimmune Therapeutics PLC
09/05/202222:36TipRanksAdaptimmune Therapeutics (ADAP) Receives a Hold from SVB SecuritiesNASDAQ:ADAPAdaptimmune Therapeutics PLC
09/05/202220:55TipRanksMizuho Securities Maintains Their Hold Rating on Adaptimmune Therapeutics (ADAP)NASDAQ:ADAPAdaptimmune Therapeutics PLC
09/05/202213:30GlobeNewswire Inc.Adaptimmune Reports First Quarter Financial Results and Business UpdateNASDAQ:ADAPAdaptimmune Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ADAP

La tua Cronologia

TG
B4T0
CuFe
BTHB
FLUXKRW
Flux
LSE
IW66
Citi Fun 25
HUOB
FETUSDT
Fetch
LSE
YY32
Sg Issuer 29
LSE
33FY
Gatwick 36
LSE
0QS4
Thurgauer Kantonalbank
USOTC
SVLLY
Savills (PK)
UNSW3
MESETH
Martian Essence
EU
FLU27
FLUXYS Belgium SA 1.75% ...
NASDAQ
HRMY
Harmony Biosciences
BOV
SPAF11
Spa Fundo Investimento I...
USOTC
IPDQF
Impedined (PK)
COIN
SEROUST
Super Zero
NASDAQ
HMTV
Hemisphere Media
TG
A3K814
Caixabank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network